JPRN-UMIN000048380
Completed
未知
Resarch of the effect of antiviral drugs on the suppression of COVID-19 persistent symptoms - Resarch of the effect of antiviral drugs on the suppression of COVID-19 persistent symptoms
agasaki University0 sites382 target enrollmentJuly 15, 2022
ConditionsCOVID-19
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- agasaki University
- Enrollment
- 382
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients diagnosed with moderate or severe COVID\-19 at the time of first visit (2\) Patients diagnosed with COVID\-19 during hospitalization (3\) Patients with COVID\-19 who were started on antiviral drugs during hospitalization (4\) Other patients deemed inappropriate as research subjects by the investigators.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation of antiviral treatment for symptomatic congenital cytomegalovirus infectioCongenital cytomegalovirus infectionJPRN-UMIN000019464Department of Pediatrics, Nagoya University Graduate School of Medicine20
Active, not recruiting
Phase 1
A Phase III Study of the Safety and Efficacy or Entecavir in Pediatric Patients with Chronic HBV-InfectioCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 14.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2009-016357-17-BEBristol-Myers Squibb International Corporation180
Completed
Phase 3
Comparative study in childrens with chronic Hepatitis B virus infection who are HBeAg positive.CTRI/2011/09/002001The pharmaceutical company sponsoring this study is BristolMyers Squibb180
Active, not recruiting
Phase 1
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-PositiveCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 12.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2009-016357-17-GRBristol-Myers Squibb International Corporation257
Active, not recruiting
Not Applicable
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infection. - NDHepatitis B VirusMedDRA version: 9.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2007-001269-14-ITBRISTOL-M.SQUIBB84